Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges
1. Takeda's Q2 2025 adjusted net profit was approximately $1.31 billion. 2. Earnings per share missed expectations, declining by 4.5% year-over-year. 3. Total quarterly sales were $7.52 billion, below consensus estimates. 4. Neuroscience revenue significantly declined due to generic erosion of Vyvanse. 5. Updated guidance indicates lower expected revenue and operating profit.